| Assessment Status |
Awaiting Full HTA Submission from Applicant |
| HTA ID |
25059 |
| Drug |
Vorasidenib |
| Brand |
Voranigo® |
| Indication |
Vorasidenib (Voranigo®) is indicated as monotherapy for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy. |
| Rapid review commissioned |
01/10/2025 |
| Rapid review completed |
23/10/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of vorasidenib compared with the current standard of care. |
| Full HTA commissioned by the HSE |
29/10/2025 |
| Pre-submission consultation with Applicant |
09/12/2025 |
